Literature DB >> 22930178

Rationale behind survivin inhibition as a potential therapeutic strategy in head and neck carcinoma too.

Gino Marioni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 22930178     DOI： 10.1007/s11912-012-0267-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  16 in total

1.  MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin.

Authors:  Ka Bian; Jing Fan; Xiang Zhang; Xin-Wei Yang; Hua-Yu Zhu; Lei Wang; Jian-Yong Sun; Yan-Ling Meng; Peng-Cheng Cui; Shi-Yin Cheng; Jian Zhang; Jing Zhao; An-Gang Yang; Rui Zhang
Journal:  FEBS Lett       Date:  2012-02-01       Impact factor: 4.124

2.  High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer.

Authors:  O P Erpolat; P U Gocun; M Akmansu; E Karakus; G Akyol
Journal:  Strahlenther Onkol       Date:  2012-02-08       Impact factor: 3.621

3.  Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma.

Authors:  Salvatore De Maria; Giuseppe Pannone; Pantaleo Bufo; Angela Santoro; Rosario Serpico; Salvatore Metafora; Corrado Rubini; Daniela Pasquali; Silvana M Papagerakis; Stefania Staibano; Gaetano De Rosa; Ernesto Farina; Monica Emanuelli; Andrea Santarelli; Maria Ada Mariggiò; Lucio Lo Russo; Lorenzo Lo Muzio
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-19       Impact factor: 4.553

Review 4.  Survivin in solid tumors: rationale for development of inhibitors.

Authors:  David N Church; Denis C Talbot
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

5.  Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants.

Authors:  Gino Marioni; Marco Agostini; Chiara Bedin; Stella Blandamura; Edoardo Stellini; Giovanni Favero; Marco Lionello; Luciano Giacomelli; Silvia Burti; Edoardo D'Angelo; Donato Nitti; Alberto Staffieri; Cosimo De Filippis
Journal:  Histopathology       Date:  2012-03-14       Impact factor: 5.087

6.  Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.

Authors:  Akihiro Miyazaki; Junichi Kobayashi; Toshihiko Torigoe; Yoshihiko Hirohashi; Takashi Yamamoto; Akira Yamaguchi; Hiroko Asanuma; Akari Takahashi; Yoshitaka Michifuri; Kenji Nakamori; Itaru Nagai; Noriyuki Sato; Hiroyoshi Hiratsuka
Journal:  Cancer Sci       Date:  2010-12-10       Impact factor: 6.716

7.  Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis.

Authors:  Gino Marioni; Andy Bertolin; Luciano Giacomelli; Rosario Marchese-Ragona; Marina Savastano; Nicola Calgaro; Filippo Marino; Cosimo De Filippis; Alberto Staffieri
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

8.  Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications.

Authors:  Youyi Dong; Li Sui; Yasuo Watanabe; Katsuyoshi Sugimoto; Masaaki Tokuda
Journal:  Anticancer Res       Date:  2002 Jul-Aug       Impact factor: 2.480

9.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.

Authors:  H Kawasaki; D C Altieri; C D Lu; M Toyoda; T Tenjo; N Tanigawa
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

Review 10.  Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges.

Authors:  Gino Marioni; Emiliano D'Alessandro; Andy Bertolin; Alberto Staffieri
Journal:  Acta Otolaryngol       Date:  2010       Impact factor: 1.494
View more
  1 in total

1.  In reply: response to Marioni.

Authors:  David N Church; Denis C Talbot
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.